Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
|
| Abstract |
Previously, we conducted a randomized phase III trial of TPF (docetaxel, cisplatin, and 5-fluorouracil) induction chemotherapy in surgically managed locally advanced oral squamous cell carcinoma (OSCC) and found no improvement in overall survival. This study reports long-term follow-up results from our initial trial. All patients had clinical stage III or IVA locally advanced OSCC. In the experimental group, patients received two cycles of TPF induction chemotherapy (75mg/m2 docetaxel d1, 75mg/m2 cisplatin d1, and 750mg/m2/day 5-fluorouracil d1-5) followed by radical surgery and post-operative radiotherapy; in the control group, patients received upfront radical surgery and post-operative radiotherapy. The primary endpoint was overall survival. Among 256 enrolled patients with a median follow-up of 70 months, estimated 5-year overall survival, disease-free survival, locoregional recurrence-free survival, and distant metastasis-free survival rates were 61.1%, 52.7%, 55.2%, and 60.4%, respectively. There were no significant differences in survival rates between experimental and control groups. However, patients with favorable pathologic responses had improved outcomes compared to those with unfavorable pathologic responses and to those in the control group. Although TPF induction chemotherapy did not improve long-term survival compared to surgery upfront in patients with stage III and IVA OSCC, a favorable pathologic response after induction chemotherapy may be used as a major endpoint and prognosticator in future studies. Furthermore, the negative results observed in this trial may be represent type II error from an underpowered study. Future larger scale phase III trials are warranted to investigate whether a significant benefit exists for TPF induction chemotherapy in surgically managed OSCC.
|
|---|---|
| Authors | Lai-ping Zhong, Chen-ping Zhang, Guo-xin Ren, Wei Guo, William N William Jr, Christopher S Hong, Jian Sun, Han-guang Zhu, Wen-yong Tu, Jiang Li, Yi-li Cai, Qiu-ming Yin, Li-zhen Wang, Zhong-he Wang, Yong-jie Hu, Tong Ji, Wen-jun Yang, Wei-min Ye, Jun Li, Yue He, Yan-an Wang, Li-qun Xu, Zhengping Zhuang, J Jack Lee, Jeffrey N Myers, Zhi-yuan Zhang |
| Journal | Oncotarget (Oncotarget) Vol. 6 Issue 21 Pg. 18707-14 (Jul 30 2015) ISSN: 1949-2553 [Electronic] United States |
| PMID | 26124084 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!